Biochemical and structural insight into the chemical resistance and cofactor specificity of the formate dehydrogenase from Starkeya novella
The FEBS Journal · 2023
DOI: 10.1111/febs.16871 ↗At a glance
Journal article in The FEBS Journal, 2023. Written by Michele Partipilo and 6 co-authors. Institution: Department of Biochemistry, Groningen Institute of Biomolecular Sciences & Biotechnology, University of Groningen, The Netherlands. Major MEDLINE topics: Formate Dehydrogenases, NAD. Cited 11 times so far (Crossref); 79 references. The full text is freely available (open access, CC BY 4.0). Funded by: Nederlandse Organisatie voor Wetenschappelijk Onderzoek, H2020 European Research Council.
Abstract (original language)
Formate dehydrogenases (Fdhs) mediate the oxidation of formate to carbon dioxide and concomitant reduction of nicotinamide adenine dinucleotide (NAD + ). The low cost of the substrate formate and importance of the product NADH as a cellular source of reducing power make this reaction attractive for biotechnological applications. However, the majority of Fdhs are sensitive to inactivation by thiol‐modifying reagents. In this study, we report a chemically resistant Fdh (Fdh SNO ) from the soil bacterium Starkeya novella strictly specific for NAD + . We present its recombinant overproduction, purification and biochemical characterization. The mechanistic basis of chemical resistance was found to be a valine in position 255 (rather than a cysteine as in other Fdhs) preventing the inactivation by thiol‐modifying compounds. To further improve the usefulness of Fdh SNO as for generating reducing power, we rationally engineered the protein to reduce the coenzyme nicotinamide adenine dinucleotide phosphate (NADP + ) with better catalytic efficiency than NAD + . The single mutation D221Q enabled the reduction of NADP + with a catalytic efficiency k CAT / K M of 0.4 s −1 ·m m −1 at 200 m m formate, while a quadruple mutant (A198G/D221Q/H379K/S380V) resulted in a fivefold increase in catalytic efficiency for NADP + compared with the single mutant. We determined the cofactor‐bound structure of the quadruple mutant to gain mechanistic evidence behind the improved specificity for NADP + . Our efforts to unravel the key residues for the chemical resistance and cofactor specificity of Fdh SNO may lead to wider use of this enzymatic group in a more sustainable (bio)manufacture of value‐added chemicals, as for instance the biosynthesis of chiral compounds.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Biochemistry, Groningen Institute of Biomolecular Sciences & Biotechnology, University of Groningen, The Netherlands.
- Polymer Chemistry and Bioengineering, Zernike Institute for Advanced Materials, Groningen, The Netherlands.
- DWI-Leibniz Institute for Interactive Materials, Aachen, Germany.
- Institute of Technical and Macromolecular Chemistry, RWTH Aachen University, Germany.
ORCID profiles: Michele Partipilo, Albert Guskov, Dirk Jan Slotboom
Funding
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- H2020 European Research Council
Cite
APA
Partipilo, M., Whittaker, J. J., Pontillo, N., Coenradij, J., Herrmann, A., Guskov, A., & Slotboom, D. J. (2023). Biochemical and structural insight into the chemical resistance and cofactor specificity of the formate dehydrogenase from Starkeya novella. The FEBS Journal. https://doi.org/10.1111/febs.16871
Vancouver
Partipilo M, Whittaker JJ, Pontillo N, Coenradij J, Herrmann A, Guskov A, et al. Biochemical and structural insight into the chemical resistance and cofactor specificity of the formate dehydrogenase from Starkeya novella. The FEBS Journal. 2023. doi:10.1111/febs.16871
BibTeX
@article{Partipilo2023,
author = {Partipilo, Michele and Whittaker, Jacob J and Pontillo, Nicola and Coenradij, Jelmer and Herrmann, Andreas and Guskov, Albert and Slotboom, Dirk Jan},
title = {Biochemical and structural insight into the chemical resistance and cofactor specificity of the formate dehydrogenase from Starkeya novella},
journal = {The FEBS Journal},
year = {2023},
doi = {10.1111/febs.16871}
}
EUVIMED